CASE STUDY

Enhancing In vivo Drug Efficacy

Use Case Highlights

The workflow below showcases the management and analysis of in vivo data using Sonrai Discovery. We utilized the data to identify the most effective treatments on tumors and assess their safety profiles. Tumor samples were collected at different stages of the study, with both imaging (IHC) and omics (RNA sequencing) data generated to explore the mechanisms of action of the therapy combinations.

Align Efficacy Studies with Precision Medicine

The use case below showcases a transformative solution that not only addresses the operational inefficiencies in tumor volume analysis and data management but also opens up new avenues in precision medicine. By aligning efficacy studies with precision medicine data, pharmaceutical companies are better equipped to develop more effective, targeted therapies, ultimately accelerating the path to discovery and improving patient outcomes. This breakthrough capability underscores Sonrai’s commitment to driving innovation and excellence in pharmaceutical research and development.

Pharmaceutical companies in this critical phase encounter challenges such as inefficient tumor volume analysis, often hindered by basic tools like Microsoft Excel and GraphPad Prism. Integrating diverse datasets from various Contract Research Organizations (CROs) further adds complexity, requiring accurate and consistent data management for early problem identification. There’s also a pressing need for efficient data cleaning and standardization to reduce manual labor and errors. Additionally, high-quality reporting is crucial for internal decision-making and communication with external partners, highlighting the need for a robust data management system.

Step-by-Step Workflow for In Vivo Drug Efficacy

Step 1: Data Cleaning and Formatting Assessment

Sonrai Discovery eliminates the need for manual aggregation and reconciliation of data from multiple Contract Research Organizations (CROs). This process traditionally consumes days or weeks and is prone to errors. Sonrai efficiently handles diverse data formats from various CROs by uploading data to our platform, swiftly identifying and resolving complexities and inconsistencies. This significantly reduces the time and effort required for data harmonization, allowing pharmaceutical companies to progress quickly to vital data analysis and development activities.

With the Sonrai Discovery pipeline in place, the frequency of incoming CRO data becomes irrelevant. It seamlessly integrates data as it arrives in any schedule or batch, ensuring consistent and automatic processing. This streamlined approach simplifies initial data handling and establishes a robust, error-resistant workflow that accelerates drug development by overcoming traditional data integration challenges.

Step 2: Enhanced Data Management

Utilising Sonrai Discovery, we refine data management practices to bolster the accuracy and consistency of tumor volume measurements. This enhancement is vital for promptly identifying potential issues and streamlining the entire data management process for improved outcomes. The platform’s capability extends to real-time data monitoring and analysis, providing teams with immediate access to processed data. This immediacy enables swift decision-making and facilitates a more dynamic approach to addressing potential issues as they arise. 

Step 3: Development of Custom Data Processing Tools

Working closely with users, Sonrai Discovery crafts a custom workflow for tumor volume analysis, featuring automated data cleaning and standardization. This personalized approach reduces analysis turnaround time and adapts efficiently to project-specific needs, demonstrating Sonrai’s commitment to flexibility and precision in data processing.

Do These Challenges Sound Familiar?

Contact our friendly team for expert guidance and transformative insights.

Step 4: Advanced Variables Analysis

Sonrai Discovery’s technology enables comprehensive analysis of variables such as drug dosage, tumor growth, response data (e.g., RECIST criteria), and biomarker levels. This analysis provides a detailed view of the drug’s impact, aiding in the nuanced understanding of treatment effects.

Step 5: Toxicity Assessment

Using Sonrai’s analytics, toxicity thresholds are established to inform optimal dosing regimens, ensuring a balance between efficacy and safety. Systematic monitoring of mouse weights offers crucial drug side effects and efficacy data.

Step 6: Enhanced Reporting Capabilities

Sonrai Discovery enables the rapid generation of comprehensive reports, streamlining communication with internal teams and external partners. This feature simplifies the presentation and sharing of critical findings, enhancing collaborative efforts.

Results

Through Sonrai’s AI-powered analytics on in vivo imaging data from mouse models, the collaboration achieves:

  • Collaborative Efficiency with Multiple CROs: Enhanced capabilities now allow for efficient collaboration with various Contract Research Organizations (CROs), significantly saving time.
  • Tailored and Precise Tumor Volume Assessment: A partnership between Sonrai and the company has resulted in a highly adaptable and precise tumor volume analysis tool. This sophisticated application efficiently processes raw data from numerous CROs, ensuring data is cleaned and standardized. The tool facilitates detailed analyses of tumor resistance and growth, equipped with advanced visualization features for chart and graph creation.
    Streamlined and
  • Accurate Data Analysis for CROs: This technological advancement streamlines the data analysis process, notably enhancing accuracy and efficiency. It minimizes the need for manual intervention in analyzing critical data from CROs.

Discover how companies worldwide grow with Sonrai. Explore all our case studies.

Get in touch

Like What You See? Let's Talk

We Listen to your problems
We give you confidence to make your decision